Rafarma Pharmaceuticals Financials
| RAFA Stock | USD 0.09 0 4.40% |
Rafarma |
Understanding current and past Rafarma Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Rafarma Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Rafarma Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Rafarma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rafarma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Rafarma Pharmaceuticals' management manipulating its earnings.
Rafarma Pharmaceuticals Stock Summary
Rafarma Pharmaceuticals competes with CbdMD, Evolus, Akanda Corp, Biofrontera, and Collegium Pharmaceutical. Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US75062C1009 |
| Business Address | 49 West 9000 |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | rafarma.si |
| Phone | 801 210 7135 |
| Currency | USD - US Dollar |
Rafarma Pharmaceuticals Key Financial Ratios
Rafarma Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Rafarma Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Rafarma Pharmaceuticals over time and compare it to other companies across industries.| Return On Equity | -7.0E-4 | |||
| Return On Asset | -4.0E-4 | |||
| Beta | -0.39 |
Rafarma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rafarma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rafarma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rafarma Pharmaceuticals competition to find correlations between indicators driving Rafarma Pharmaceuticals's intrinsic value. More Info.Rafarma Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rafarma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rafarma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Rafarma Pharmaceuticals Systematic Risk
Rafarma Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rafarma Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Rafarma Pharmaceuticals correlated with the market. If Beta is less than 0 Rafarma Pharmaceuticals generally moves in the opposite direction as compared to the market. If Rafarma Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rafarma Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rafarma Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Rafarma Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Rafarma Pharmaceuticals December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Rafarma Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Rafarma Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Rafarma Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Rafarma Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Rafarma Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 20.27 | |||
| Information Ratio | 0.1199 | |||
| Maximum Drawdown | 79.73 | |||
| Value At Risk | (23.33) | |||
| Potential Upside | 34.15 |
Complementary Tools for Rafarma Pink Sheet analysis
When running Rafarma Pharmaceuticals' price analysis, check to measure Rafarma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rafarma Pharmaceuticals is operating at the current time. Most of Rafarma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rafarma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rafarma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rafarma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |